Pub Date : 2014-11-28DOI: 10.2174/1876388X01406010017
M. Vorster, A. Stoltz, A. Jacobs, M. Sathekge
Introduction: A 37-year-old man was referred for PET/CT with the following diagnostic challenge: a longstanding smoking history, histologically confirmed TB and sarcoidosis with worsening chest-related symptoms and a non-responsive right upper lobe lung lesion (as detected on CT). Materials and Methods: PET/CT imaging was performed with 18 F-FDG and followed by imaging with 18 F-fluoroethyl- choline in an attempt to better characterize the lung lesion. This was followed by biopsies of the right upper lobe nodule, the pleura and a brain lesion. Results: Both tracers demonstrated increased uptake in the lung lesion and in multiple lymph node groups. Histology revealed the presence of a granulomatous disease in the lung lesion, the pleura and in the brain. Follow-up evaluation with 18 F-fluoroethyl-choline PET/CT demonstrated some improvement, which correlated with clinical improvement. Conclusion: Tuberculous lesions demonstrate increased accumulation of 18 F-fluoroethyl-choline on PET/CT, which may be useful in the evaluation of treatment response. When used in combination with 18 F-FDG, it could be of value in
简介:一名37岁男性因以下诊断挑战被转介PET/CT:长期吸烟史，组织学证实结核病和结节病，胸部相关症状恶化，右上肺无反应性病变(CT上发现)。材料和方法:采用18 F-FDG进行PET/CT成像，然后用18 f -氟乙基胆碱成像，试图更好地表征肺部病变。随后对右上肺叶结节、胸膜和脑病变进行活检。结果:两种示踪剂在肺病变和多淋巴结组均显示摄取增加。组织学显示肺部病变、胸膜和脑部有肉芽肿性病变。随访评价18f -氟乙基胆碱PET/CT显示有一定改善，与临床改善相关。结论:结核病变在PET/CT上表现为18 f -氟乙基胆碱积累增加，可用于评价治疗效果。当与18f - fdg结合使用时，它可以在
{"title":"Imaging of Pulmonary Tuberculosis with 18F-Fluoro-Deoxy-Glucose and 18F-Ethylcholine","authors":"M. Vorster, A. Stoltz, A. Jacobs, M. Sathekge","doi":"10.2174/1876388X01406010017","DOIUrl":"https://doi.org/10.2174/1876388X01406010017","url":null,"abstract":"Introduction: A 37-year-old man was referred for PET/CT with the following diagnostic challenge: a longstanding smoking history, histologically confirmed TB and sarcoidosis with worsening chest-related symptoms and a non-responsive right upper lobe lung lesion (as detected on CT). Materials and Methods: PET/CT imaging was performed with 18 F-FDG and followed by imaging with 18 F-fluoroethyl- choline in an attempt to better characterize the lung lesion. This was followed by biopsies of the right upper lobe nodule, the pleura and a brain lesion. Results: Both tracers demonstrated increased uptake in the lung lesion and in multiple lymph node groups. Histology revealed the presence of a granulomatous disease in the lung lesion, the pleura and in the brain. Follow-up evaluation with 18 F-fluoroethyl-choline PET/CT demonstrated some improvement, which correlated with clinical improvement. Conclusion: Tuberculous lesions demonstrate increased accumulation of 18 F-fluoroethyl-choline on PET/CT, which may be useful in the evaluation of treatment response. When used in combination with 18 F-FDG, it could be of value in","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"6 1","pages":"17-21"},"PeriodicalIF":0.0,"publicationDate":"2014-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68128148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-06-27DOI: 10.2174/1876388X01406010012
A. Amin, Mahasen Amin, E. Ahmed
Purpose: To investigate the impact of quantitative FDG-Metabolic activity of non-iodine avid Loco-regional recurrence (LRR; thyroid recurrence and/or cervical node metastasis) on therapy selection in thyroid cancer patients with elevated thyroglobulin (TG). Methods: Forty thyroid cancer (33 papillary and 7 follicular) patients who underwent FDG PET/CT were studied (with TSH>30 mU/L). Those with only LRR were classified according to maxSUV (cut-off level 5) into high and low metabolic activity lesions (HMA L their therapy outcome was compared with histopathologic findings and/or follow-up routine evaluation. Results: Only LRRs was found in 20 patients (17 papillary and 3 follicular) with diagnostic accuracy of FDG PET/CT of 100 %. 14/20 patients belonged to HMA where surgical neck exploration was done while in the remaining 6 patients with LMA empirical high dose of radioactive iodine-131 was given based on the assumption of the presence of a mixture of undifferentiated and differentiated thyroid cancer cells; though their post-therapy scan was negative but declined TG- levels were elicited in their follow-up (base-line 27.7±2.4 and at follow-up 6.8±1.4 ng/ml; P 0.02). Conclusion: Max-SUV based classification of non-iodine avid LRR might improve the diagnostic accuracy FDG PET/CT in a therapeutically relevant way in DTC-patients by precisely localizing them with subsequent surgical guidance in HMA lesions while those with LMA could benefit from further RA-131 therapy.
{"title":"Low FDG Metabolic Activity of Loco-Regional Recurrence in ThyroidCancer Patients; Is Iodine-131 has a Potentiality?","authors":"A. Amin, Mahasen Amin, E. Ahmed","doi":"10.2174/1876388X01406010012","DOIUrl":"https://doi.org/10.2174/1876388X01406010012","url":null,"abstract":"Purpose: To investigate the impact of quantitative FDG-Metabolic activity of non-iodine avid Loco-regional recurrence (LRR; thyroid recurrence and/or cervical node metastasis) on therapy selection in thyroid cancer patients with elevated thyroglobulin (TG). Methods: Forty thyroid cancer (33 papillary and 7 follicular) patients who underwent FDG PET/CT were studied (with TSH>30 mU/L). Those with only LRR were classified according to maxSUV (cut-off level 5) into high and low metabolic activity lesions (HMA L their therapy outcome was compared with histopathologic findings and/or follow-up routine evaluation. Results: Only LRRs was found in 20 patients (17 papillary and 3 follicular) with diagnostic accuracy of FDG PET/CT of 100 %. 14/20 patients belonged to HMA where surgical neck exploration was done while in the remaining 6 patients with LMA empirical high dose of radioactive iodine-131 was given based on the assumption of the presence of a mixture of undifferentiated and differentiated thyroid cancer cells; though their post-therapy scan was negative but declined TG- levels were elicited in their follow-up (base-line 27.7±2.4 and at follow-up 6.8±1.4 ng/ml; P 0.02). Conclusion: Max-SUV based classification of non-iodine avid LRR might improve the diagnostic accuracy FDG PET/CT in a therapeutically relevant way in DTC-patients by precisely localizing them with subsequent surgical guidance in HMA lesions while those with LMA could benefit from further RA-131 therapy.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"6 1","pages":"12-16"},"PeriodicalIF":0.0,"publicationDate":"2014-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68128104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-04-04DOI: 10.2174/1876388X01406010006
Christa Zinn, M. Vorster, M. Sathekge
Results: Only 4 patients had one spinal lesion, while 12 (75%) patients had 2 or more lesions. Those patients that had three or more lesions demonstrated intense FDG uptake with a median of 11.34 (3.8-20.9). Ten (62%) of the patients had both spinal and extraspinal lesions. In most of the cases (75%), the lumbar spine was involved as opposed to the thoracic vertebrae. 18F-FDG PET detected all 39/39 (100%) clinically (sites of disease that resulted in symptoms or signs such as pain, swelling, neurological fallout etc.) and histologically (as reported by the laboratory) observed spinal sites. The median of the SUVmax for spinal lesions was 6.06 (ranging from 2.63 to 16.78). Diagnostic CT reported corresponding morphological changes in only 27 (69%) of the spinal sites identified on 18F-FDG PET/CT. 18F-FDG PET/CT detected 60 of 60 (100%) clinically observed extraspinal sites including pulmonary TB, nodal disease and other musculoskeletal sites versus the 43 of 60 (71%) detected by diagnostic CT only. The median of the SUVmax was 3.61 for nodal sites (ranging from 1.71 to 10.79) and 3.38 for pulmonary sites (ranging from 1.23 to 5.93). Conclusion: The results suggest that 18F-FDG PET/CT is more effective compared to diagnostic CT only in the identification of sites of active disease and contributes to a better evaluation of extraspinal involvement in TB patients. It also appears to be a very promising imaging modality for the identification of the most appropriate biopsy site, staging disease, predicting multi-drug resistance and monitoring response to therapy.
{"title":"Spinal Tuberculosis Evaluated by Means of 18F-FDG PET/CT: Pilot Study","authors":"Christa Zinn, M. Vorster, M. Sathekge","doi":"10.2174/1876388X01406010006","DOIUrl":"https://doi.org/10.2174/1876388X01406010006","url":null,"abstract":"Results: Only 4 patients had one spinal lesion, while 12 (75%) patients had 2 or more lesions. Those patients that had three or more lesions demonstrated intense FDG uptake with a median of 11.34 (3.8-20.9). Ten (62%) of the patients had both spinal and extraspinal lesions. In most of the cases (75%), the lumbar spine was involved as opposed to the thoracic vertebrae. 18F-FDG PET detected all 39/39 (100%) clinically (sites of disease that resulted in symptoms or signs such as pain, swelling, neurological fallout etc.) and histologically (as reported by the laboratory) observed spinal sites. The median of the SUVmax for spinal lesions was 6.06 (ranging from 2.63 to 16.78). Diagnostic CT reported corresponding morphological changes in only 27 (69%) of the spinal sites identified on 18F-FDG PET/CT. 18F-FDG PET/CT detected 60 of 60 (100%) clinically observed extraspinal sites including pulmonary TB, nodal disease and other musculoskeletal sites versus the 43 of 60 (71%) detected by diagnostic CT only. The median of the SUVmax was 3.61 for nodal sites (ranging from 1.71 to 10.79) and 3.38 for pulmonary sites (ranging from 1.23 to 5.93). Conclusion: The results suggest that 18F-FDG PET/CT is more effective compared to diagnostic CT only in the identification of sites of active disease and contributes to a better evaluation of extraspinal involvement in TB patients. It also appears to be a very promising imaging modality for the identification of the most appropriate biopsy site, staging disease, predicting multi-drug resistance and monitoring response to therapy.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"6 1","pages":"6-11"},"PeriodicalIF":0.0,"publicationDate":"2014-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68128037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-01-24DOI: 10.2174/1876388X01406010001
B. Palumbo, D. Siepi, S. Amici, H. Sinzinger
Introduction and Objective: To investigate perfusion in dementia and Parkinson's disease (PD) we performed 99m Tc-HMPAO brain SPECT with semiquantitative analysis of Brodmann areas in different aged patients. Materials and Methods: We retrospectively evaluated 104 patients, 30 with Alzheimer's disease (AD), 26 with frontotemporal dementia (FTD), 25 with mild cognitive impairment (MCI), 23 with PD, undergoing 99m Tc-HMPAO brain SPECT. SPECT data of 3D ROIs of predefined Brodmann's area templates were compared with those of a database of age and sex-matched healthy subjects. Median values and inter-quartile ranges were used to summarize ROIs of Brodmann areas (L= left, R= right) in the different groups; Kruskal-Wallis test evaluated difference between medians (p< 0.05 as level of significance). Results: Different Brodmann areas were significantly hypoperfused in the different pathological categories. Both Areas 37 (temporal gyrus) and 39 (angular gyrus) of AD patients were hypoperfused (p<0.05) compared with MCI and FTD, both Areas 40 (supramarginal gyrus) and Area 39 L of AD patients were (p<0.01) hypoperfused comparing with PD; in FTD both Areas 47 (frontal association cortex) showed significantly decreased (p<0.05) perfusion compared with MCI and Area 11 R (frontal-orbital gyrus) comparing with PD. Conclusion: Perfusion impairment of specific parietal and temporal areas characterized AD, while frontal area hypoperfusion was present in FTD. No specific hypoperfusion pattern was evident for MCI and PD.
{"title":"Differential Diagnosis Between Neurodegenerative Dementia Disorders and Parkinson’s Disease Using 99mTc-HMPAO SPECT","authors":"B. Palumbo, D. Siepi, S. Amici, H. Sinzinger","doi":"10.2174/1876388X01406010001","DOIUrl":"https://doi.org/10.2174/1876388X01406010001","url":null,"abstract":"Introduction and Objective: To investigate perfusion in dementia and Parkinson's disease (PD) we performed 99m Tc-HMPAO brain SPECT with semiquantitative analysis of Brodmann areas in different aged patients. Materials and Methods: We retrospectively evaluated 104 patients, 30 with Alzheimer's disease (AD), 26 with frontotemporal dementia (FTD), 25 with mild cognitive impairment (MCI), 23 with PD, undergoing 99m Tc-HMPAO brain SPECT. SPECT data of 3D ROIs of predefined Brodmann's area templates were compared with those of a database of age and sex-matched healthy subjects. Median values and inter-quartile ranges were used to summarize ROIs of Brodmann areas (L= left, R= right) in the different groups; Kruskal-Wallis test evaluated difference between medians (p< 0.05 as level of significance). Results: Different Brodmann areas were significantly hypoperfused in the different pathological categories. Both Areas 37 (temporal gyrus) and 39 (angular gyrus) of AD patients were hypoperfused (p<0.05) compared with MCI and FTD, both Areas 40 (supramarginal gyrus) and Area 39 L of AD patients were (p<0.01) hypoperfused comparing with PD; in FTD both Areas 47 (frontal association cortex) showed significantly decreased (p<0.05) perfusion compared with MCI and Area 11 R (frontal-orbital gyrus) comparing with PD. Conclusion: Perfusion impairment of specific parietal and temporal areas characterized AD, while frontal area hypoperfusion was present in FTD. No specific hypoperfusion pattern was evident for MCI and PD.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"9 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2014-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-07-12DOI: 10.2174/1876388X01305010001
P. Ubl, R. Sareshgi, A. Schiefer, D. Lai, B. Kiesewetter, X. Liu, M. Raderer, S. Li
Aim: Vascular endothelial growth factor (VEGF) and VEGF receptor are over-expressed in lymphomagenesis. The aim of this study was to evaluate the usefulness of 123 I-VEGF165 scintigraphy for imaging of B-cell lymphoma of the Mucosa-Associated Lymphoid TissueMALT lymphoma). Methods: Three Patients (age range: 52-71 years) with histopathological verified MALT lymphoma were included in the study. Two patients had disseminated MALT-lymphoma and one patient had parotid MALT-lymphoma with involvement of cervical lymph nodes. Recombinant VEGF165 was radiolabeled with 123 I by electrophilic radioiodination using the chloramine T method. Each patient received 172 MBq (<130 pmole (< 5 � g) VEGF165 per patient) of 123 I-VEGF165. Dynamic acquisition was initiated immediately after administration and carried out until 30 minutes post injection. Whole-body images were acquired in anterior and posterior views at various times points post injection (p.i.). SPECT was performed 1 hour p.i. Results: None of the patients with MALT lymphoma showed pathologically increased focal 123 I-VEGF uptake in verified tumor lesions. No clinical adverse reaction and no side-effects after intravenous application of 123 I-VEGF165 were found. Conclusions: Our results suggest that 123 I-VEGF165 scintigraphy does not visualize B-cell lymphomas of MALT type.
{"title":"123I-Vascular Endothelial Growth Factor-165 (123I-VEGF165) Scintigraphyfor Visualisation of Extranodal Marginal Zone B-Cell Lymphoma of theMucosa-Associated Lymphoid Tissue (MALT) Type","authors":"P. Ubl, R. Sareshgi, A. Schiefer, D. Lai, B. Kiesewetter, X. Liu, M. Raderer, S. Li","doi":"10.2174/1876388X01305010001","DOIUrl":"https://doi.org/10.2174/1876388X01305010001","url":null,"abstract":"Aim: Vascular endothelial growth factor (VEGF) and VEGF receptor are over-expressed in lymphomagenesis. The aim of this study was to evaluate the usefulness of 123 I-VEGF165 scintigraphy for imaging of B-cell lymphoma of the Mucosa-Associated Lymphoid TissueMALT lymphoma). Methods: Three Patients (age range: 52-71 years) with histopathological verified MALT lymphoma were included in the study. Two patients had disseminated MALT-lymphoma and one patient had parotid MALT-lymphoma with involvement of cervical lymph nodes. Recombinant VEGF165 was radiolabeled with 123 I by electrophilic radioiodination using the chloramine T method. Each patient received 172 MBq (<130 pmole (< 5 � g) VEGF165 per patient) of 123 I-VEGF165. Dynamic acquisition was initiated immediately after administration and carried out until 30 minutes post injection. Whole-body images were acquired in anterior and posterior views at various times points post injection (p.i.). SPECT was performed 1 hour p.i. Results: None of the patients with MALT lymphoma showed pathologically increased focal 123 I-VEGF uptake in verified tumor lesions. No clinical adverse reaction and no side-effects after intravenous application of 123 I-VEGF165 were found. Conclusions: Our results suggest that 123 I-VEGF165 scintigraphy does not visualize B-cell lymphomas of MALT type.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"5 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2013-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-06-01DOI: 10.2174/1876388X01204010014
C. Grana, M. Chinol, C. Cicco, M. Bartolomei, M. Cremonesi, L. Bodei, P. Rocca, M. Pacifici, Simone Tiberini, S. Baio, G. Broggi, S. Severi, G. Paganelli
Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma (GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 90 Y- biotin. Methods: The present study reviews objective response and overall survival rates in 502 glioblastoma patients treated with 3-step radioimmunotherapy in our institute from December 1994 to December 2005. Patients underwent standard treatment before receiving Pretargeted Antibody-Guided Radionuclide Therapy with 90 Y-biotin (PAGRIT ® ). Results: Of the 502 patients, 272 (54%) were evaluable for response and 375 (75%) for overall survival. 174 patients (64%) continued to progress after PAGRIT ® , 77 (28%) obtained disease stabilization, and 21 (8%) showed objective tumor regression. Survival of the 375 evaluable patients was 98.4% at 6 months, 79.2% at 12 months, 51.7% at 18 months, and 30.7% at 24 months after the first cycle of PAGRIT ® . All 375 received 3-step PAGRIT ® at recurrence of GBM. The median survival time from diagnosis was 19 months. Conclusion: The results from this retrospective analysis suggest that 90 Y-biotin PAGRIT ® interferes with the progression of glioblastoma, prolonging survival in a larger number of patients. Our analysis forms the basis for further prospective trials, where radioimmunotherapy, which is known to be more effective in minimal residual disease, could be offered immediately after surgery.
背景:在复发性胶质母细胞瘤(GBM)患者中应用三步亲和素-生物素预靶向方法，第一步使用生物素化抗tenascin单克隆抗体，然后使用亲和素和90y -生物素进行预靶向。方法:回顾我院1994年12月至2005年12月502例接受三步放射免疫治疗的胶质母细胞瘤患者的客观疗效和总生存率。患者在接受预靶向抗体引导放射性核素90 y生物素治疗(PAGRIT®)之前接受标准治疗。结果:在502例患者中，272例(54%)可评估缓解，375例(75%)可评估总生存期。174例患者(64%)在PAGRIT®后继续进展，77例(28%)获得疾病稳定，21例(8%)显示客观肿瘤消退。在第一个PAGRIT®周期后，375名可评估患者的6个月生存率为98.4%，12个月为79.2%，18个月为51.7%，24个月为30.7%。所有375例GBM复发患者均接受了3步PAGRIT治疗。诊断后的中位生存时间为19个月。结论:这项回顾性分析的结果表明，90 y -生物素PAGRIT®干扰胶质母细胞瘤的进展，延长了大量患者的生存期。我们的分析为进一步的前瞻性试验奠定了基础，在这些试验中，放射免疫疗法(已知对最小残留疾病更有效)可以在手术后立即提供。
{"title":"Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival","authors":"C. Grana, M. Chinol, C. Cicco, M. Bartolomei, M. Cremonesi, L. Bodei, P. Rocca, M. Pacifici, Simone Tiberini, S. Baio, G. Broggi, S. Severi, G. Paganelli","doi":"10.2174/1876388X01204010014","DOIUrl":"https://doi.org/10.2174/1876388X01204010014","url":null,"abstract":"Background: The 3-step avidin-biotin pretargeting approach is applied in patients with recurrent glioblastoma (GBM), using biotinylated anti-tenascin monoclonal antibody as the first step of pretargeting followed by avidin and 90 Y- biotin. Methods: The present study reviews objective response and overall survival rates in 502 glioblastoma patients treated with 3-step radioimmunotherapy in our institute from December 1994 to December 2005. Patients underwent standard treatment before receiving Pretargeted Antibody-Guided Radionuclide Therapy with 90 Y-biotin (PAGRIT ® ). Results: Of the 502 patients, 272 (54%) were evaluable for response and 375 (75%) for overall survival. 174 patients (64%) continued to progress after PAGRIT ® , 77 (28%) obtained disease stabilization, and 21 (8%) showed objective tumor regression. Survival of the 375 evaluable patients was 98.4% at 6 months, 79.2% at 12 months, 51.7% at 18 months, and 30.7% at 24 months after the first cycle of PAGRIT ® . All 375 received 3-step PAGRIT ® at recurrence of GBM. The median survival time from diagnosis was 19 months. Conclusion: The results from this retrospective analysis suggest that 90 Y-biotin PAGRIT ® interferes with the progression of glioblastoma, prolonging survival in a larger number of patients. Our analysis forms the basis for further prospective trials, where radioimmunotherapy, which is known to be more effective in minimal residual disease, could be offered immediately after surgery.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"4 1","pages":"14-20"},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-04-13DOI: 10.2174/1876388X01204010005
O. Kraft, M. Havel
Aim: Assess the role of planar lymphoscintigraphy and fusion imaging of SPECT/CT in sentinel lymph node (SLN) identification in patients with breast cancer. Methods: Planar scintigraphy and hybrid modality SPECT/CT were performed in 223 consecutive women with breast cancer (mean age 59,5 yrs with range 25 - 82 years). In 190 women with a palpable mass radiocolloid was injected in four peritumoral sites and one subdermal injection above the tumour (GROUP A), in 33 women with nonpalpable tumour radiotracer was injected in four subareolar sites (GROUP B). Planar and SPECT/CT images were interpreted separately by two nuclear medicine physicians. Ability of these two techniques to image SLN was compared. Results: In GROUP A the overall hot LN detection rate by planar and SPECT-CT lymphoscintigraphy was 87,9 % (167 patients). In 10 patients (5,3 %), hot LNs were detected only by SPECT-CT. 18 (5,3 %) foci of uptake in 13 (6,8 %) patients interpreted on planar images as hot LNs were found to be false positive non-nodal sites of uptake when further assessed on SPECT/CT. In GROUP B the overall hot LN detection rate on planar and SPECT-CT was 97 % (32 patients). In one (3,0 %) patient hot LNs were identified only on SPECT/CT. Four (6,6 %) foci of uptake in four (12,1 %) patients were found to be false positive when further correlated with SPECT/CT. Differences in detection of SLNs between planar and SPECT/CT imaging in all 223 patients were statistically significant (P< 0.001). Conclusion: In some patients with breast cancer SPECT/CT improves the detection of sentinel lymph nodes. It can image nodes not visible on planar scintigrams, exclude false positive uptake and exactly localize axillary and non-axillary SLN.
{"title":"Sentinel Lymph Node Identification in Breast Cancer - Comparison of Planar Scintigraphy and SPECT/CT","authors":"O. Kraft, M. Havel","doi":"10.2174/1876388X01204010005","DOIUrl":"https://doi.org/10.2174/1876388X01204010005","url":null,"abstract":"Aim: Assess the role of planar lymphoscintigraphy and fusion imaging of SPECT/CT in sentinel lymph node (SLN) identification in patients with breast cancer. Methods: Planar scintigraphy and hybrid modality SPECT/CT were performed in 223 consecutive women with breast cancer (mean age 59,5 yrs with range 25 - 82 years). In 190 women with a palpable mass radiocolloid was injected in four peritumoral sites and one subdermal injection above the tumour (GROUP A), in 33 women with nonpalpable tumour radiotracer was injected in four subareolar sites (GROUP B). Planar and SPECT/CT images were interpreted separately by two nuclear medicine physicians. Ability of these two techniques to image SLN was compared. Results: In GROUP A the overall hot LN detection rate by planar and SPECT-CT lymphoscintigraphy was 87,9 % (167 patients). In 10 patients (5,3 %), hot LNs were detected only by SPECT-CT. 18 (5,3 %) foci of uptake in 13 (6,8 %) patients interpreted on planar images as hot LNs were found to be false positive non-nodal sites of uptake when further assessed on SPECT/CT. In GROUP B the overall hot LN detection rate on planar and SPECT-CT was 97 % (32 patients). In one (3,0 %) patient hot LNs were identified only on SPECT/CT. Four (6,6 %) foci of uptake in four (12,1 %) patients were found to be false positive when further correlated with SPECT/CT. Differences in detection of SLNs between planar and SPECT/CT imaging in all 223 patients were statistically significant (P< 0.001). Conclusion: In some patients with breast cancer SPECT/CT improves the detection of sentinel lymph nodes. It can image nodes not visible on planar scintigrams, exclude false positive uptake and exactly localize axillary and non-axillary SLN.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"4 1","pages":"5-13"},"PeriodicalIF":0.0,"publicationDate":"2012-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-03-09DOI: 10.2174/1876388X01204010001
B. Iqbal, G. Currie, H. Bashir, U. Afzal, M. Nawaz, S. Mansoor, Janelle Wheat, M. Younis
Introduction: The malignant lymphomas are the fifth most common neoplasm in both men and women. Staging, re-staging and treatment response evaluation pose a difficult task in many patients of lymphomas. Histological variants in both Hodgkin's and Non-Hodgkin's types of lymphoma greatly affect the response to treatment and overall prognosis. Objective: This study was conducted to correlate the degree of abnormal Gallium-67 uptake with the histological variants of non-Hodgkin's lymphoma. This project was a part of the study to see the ability of Gallium-67 scintigraphy to predict the response to chemotherapy early in the course of therapy. Material & Methods: 65 patients were included in the study with a mean age of 25 years. All patients had undergone medical imaging, bone marrow biopsy and histopathology. Results: Sixty-five patients were classified according to the REAL classification. 11 patients were of T-cell type, 50 were of B-cell type and 4 were anaplastic. 46 showed gallium-67 uptake in the lesions, whereas 19 (29.2%) had no discernable Gallium-67 uptake.
{"title":"Gallium-67 Uptake in Histological Variants of Non-Hodgkin's Lymphoma - A Correlative Study","authors":"B. Iqbal, G. Currie, H. Bashir, U. Afzal, M. Nawaz, S. Mansoor, Janelle Wheat, M. Younis","doi":"10.2174/1876388X01204010001","DOIUrl":"https://doi.org/10.2174/1876388X01204010001","url":null,"abstract":"Introduction: The malignant lymphomas are the fifth most common neoplasm in both men and women. Staging, re-staging and treatment response evaluation pose a difficult task in many patients of lymphomas. Histological variants in both Hodgkin's and Non-Hodgkin's types of lymphoma greatly affect the response to treatment and overall prognosis. Objective: This study was conducted to correlate the degree of abnormal Gallium-67 uptake with the histological variants of non-Hodgkin's lymphoma. This project was a part of the study to see the ability of Gallium-67 scintigraphy to predict the response to chemotherapy early in the course of therapy. Material & Methods: 65 patients were included in the study with a mean age of 25 years. All patients had undergone medical imaging, bone marrow biopsy and histopathology. Results: Sixty-five patients were classified according to the REAL classification. 11 patients were of T-cell type, 50 were of B-cell type and 4 were anaplastic. 46 showed gallium-67 uptake in the lesions, whereas 19 (29.2%) had no discernable Gallium-67 uptake.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"4 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2012-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-11-11DOI: 10.2174/1876388X01103010025
P. Lafont, I. Morelec, M. Fraysse, P. Got, C. Houzard, Antoine Confavreux, Antoine Foucher, F. Giammarile
Purpose: 18 F-FDG labelled leukocytes using PET/CT have been suggested as a radiotracer that offer specificity and high quality images for localization of inflammation and infection. The purpose of this in vitro study was to determine the functional integrity of leukocytes after labelling with 18 F-FDG. Materials and Methods: Leukocytes were separated from whole blood donated by 6 healthy volunteers and labelled with 18 F-FDG. The tests included viability, chemotaxis and phagocytosis of the cells. Trypan Blue was used for viability test. Directional migration was done using chemotaxis under agarose technique. Opsonised zymosan particles were used for phagocytosis assay. Results: Average labelling efficiency (LE) was 90.8%. Viability of 18 F-FDG labelled leukocytes one hour after labelling was superior to 99%. Chemotaxis assay showed cells were attracted by chemoattractant after 4 hours of incubation. Labelled cells were found to continue further migration after 24 hours with approximately the same pattern and distance as those of unlabelled cells. Zymosan particles were phagocytosed by the labelled leukocytes. Conclusion: Our study showed that 18 F-FDG labelled leukocytes preserved their functional integrity. The labelled cells were viable, responded to inflammatory signals and reacted by engulfing zymosan particles. The results of these in vitro tests suggest that 18 F-FDG labelled leukocytes could be used for localization of infections and inflammations.
{"title":"18FFDG Labelled Leukocytes In Vitro Functional Tests: Viability,Chemotaxis and Phagocytosis Assays","authors":"P. Lafont, I. Morelec, M. Fraysse, P. Got, C. Houzard, Antoine Confavreux, Antoine Foucher, F. Giammarile","doi":"10.2174/1876388X01103010025","DOIUrl":"https://doi.org/10.2174/1876388X01103010025","url":null,"abstract":"Purpose: 18 F-FDG labelled leukocytes using PET/CT have been suggested as a radiotracer that offer specificity and high quality images for localization of inflammation and infection. The purpose of this in vitro study was to determine the functional integrity of leukocytes after labelling with 18 F-FDG. Materials and Methods: Leukocytes were separated from whole blood donated by 6 healthy volunteers and labelled with 18 F-FDG. The tests included viability, chemotaxis and phagocytosis of the cells. Trypan Blue was used for viability test. Directional migration was done using chemotaxis under agarose technique. Opsonised zymosan particles were used for phagocytosis assay. Results: Average labelling efficiency (LE) was 90.8%. Viability of 18 F-FDG labelled leukocytes one hour after labelling was superior to 99%. Chemotaxis assay showed cells were attracted by chemoattractant after 4 hours of incubation. Labelled cells were found to continue further migration after 24 hours with approximately the same pattern and distance as those of unlabelled cells. Zymosan particles were phagocytosed by the labelled leukocytes. Conclusion: Our study showed that 18 F-FDG labelled leukocytes preserved their functional integrity. The labelled cells were viable, responded to inflammatory signals and reacted by engulfing zymosan particles. The results of these in vitro tests suggest that 18 F-FDG labelled leukocytes could be used for localization of infections and inflammations.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"3 1","pages":"25-29"},"PeriodicalIF":0.0,"publicationDate":"2011-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-10-07DOI: 10.2174/1876388X01103010019
S. Lehnert, Yongbiao Li, E. Bump, Bill Riddoch, A. Chenite, M. Shive
The intent of this study was to optimise conditions for the use of 125 IUdR in the treatment of cancer. The radiopharmaceutical plus a biomodulator, methotrexate (MTX) was delivered by intra-tumoral injection of a thermosensitive hydrogel forming a slow release depot of 125 IUdR and MTX in the tumor. Methods: The C6 rat glioblastoma was implanted intra-cranially. A chitosan polymer was used to formulate a biodegradable and biocompatible implant for controlled intra-tumoral delivery of 125 IUdR plus MTX. Results: Intratumoral implant of hydrogel loaded with 7.0 -7.4 MBq of 125 IUdR resulted in survival of 20% of treated animals to 180 days after tumor implant. Simultaneous delivery of MTX increased the number of rats that were effectively cured, to 40%. Conclusion: Using an injectable thermolabile hydrogel as vehicle for 125 IUdR delivery a higher level of tumor control was achieved in a rat glioma model than had been previously reported.
{"title":"125I-Iododeoxyuridine for the Treatment of a Brain Tumor Model:Selection of Conditions for Optimal Effectiveness","authors":"S. Lehnert, Yongbiao Li, E. Bump, Bill Riddoch, A. Chenite, M. Shive","doi":"10.2174/1876388X01103010019","DOIUrl":"https://doi.org/10.2174/1876388X01103010019","url":null,"abstract":"The intent of this study was to optimise conditions for the use of 125 IUdR in the treatment of cancer. The radiopharmaceutical plus a biomodulator, methotrexate (MTX) was delivered by intra-tumoral injection of a thermosensitive hydrogel forming a slow release depot of 125 IUdR and MTX in the tumor. Methods: The C6 rat glioblastoma was implanted intra-cranially. A chitosan polymer was used to formulate a biodegradable and biocompatible implant for controlled intra-tumoral delivery of 125 IUdR plus MTX. Results: Intratumoral implant of hydrogel loaded with 7.0 -7.4 MBq of 125 IUdR resulted in survival of 20% of treated animals to 180 days after tumor implant. Simultaneous delivery of MTX increased the number of rats that were effectively cured, to 40%. Conclusion: Using an injectable thermolabile hydrogel as vehicle for 125 IUdR delivery a higher level of tumor control was achieved in a rat glioma model than had been previously reported.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"3 1","pages":"19-24"},"PeriodicalIF":0.0,"publicationDate":"2011-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：